Novartis
NEWS
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
Ziextenzo (pegfilgrastim) is a long-acting version of filgrastim and is indicated to decrease the incidence of infection in cancer patients.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
Novartis said it will work diligently with the FDA to resolve the partial clinical hold and resume the study.
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
The agreement revolves around the development and commercialization of Pliant’s preclinical candidate, PLN-1474, and up to three more integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis.
JOBS
IN THE PRESS